INTRODUCTION 1
Herpes simplex virus (HSV) is a neuroinvasive human pathogen that critically depends on 2 efficient infection of distinct target cells within a host. At the time of primary lytic infection, 3 HSV replicates in peripheral mucocutaneuos tissues and releases virions. A decisive 4 characteristic of HSV infections in animals and humans is the establishment of a life-long 5 latency. HSV spreads from infected epithelial cells to axons of sensory neurons innervating the 6 site of the primary infection, followed by retrograde transport to respective dorsal root ganglia 7 (12). Recurrent infections results from reactivation in neuronal cells, followed by virus 8 replication and anterograde transport to cells at peripheral sites innervated by respective neurons. 9
Transmission between cells without diffusion through the extracellular environment represents a 10 dircharge of the virus inoculum. The delivered inoculum induced infection rates > 94 % as 1 assessed by culture of vaginal lavage. Mice were examined daily after viral inoculation for loss of 2 weight, vulvitis/vaginitis (redness, mucopurulent discharge and signs of inflammation) and 3 neurological disease. Mice displaying any of these symptoms were sacrificed immediately. Mice 4 were passively immunized by intravenous (i.v.) injection of purified mAb 2c either 24 h prior to 5 viral inoculation for immune prophylaxis or 24 h, 40 h, and 56 h after viral infection for 6 therapeutic treatment. Mice were assessed for infection by determination of virus titers from 7 vaginal irrigations obtained on days 1, 2, 4, 6 and 8 after infection and at the time of death using 8 the endpoint dilution assay on Vero cells. Viral loads in organs (spleen, adrenal gland, lung heart, 9 liver, kidney, spinal cord, and brain) of sacrificed mice were determined after homogenization of 10 organs by titration on Vero cell monolayers as described elsewhere (42). Each test and control 11 group contained 9-10 animals with detectable HSV-1 infection. 12
RESULTS 1
Mapping and analysis of the gB epitope recognized by mAb 2c. 2 The recently determined crystal structure of the ectodomain of gB from HSV type 1 (HSV-1) 3 revealed a multi-domain trimer with five distinct structural domains: domain I (base), domain II 4 (middle), domain III (core), domain IV (crown), and domain V (arm) (25). To characterize the 5 neutralizing epitope of mAb 2c, we tested its reactivity with recombinant gB(730t) (4) in Western 6 blot analysis either under reducing or non-reducing conditions. As controls we used mAb H1817, 7 recognizing a linear epitope (4) and mAb H126 recognizing a discontinuous epitope (34). A 8 typical staining pattern for a linear epitope was obtained in Western blot analysis with mAb 9
H1817 showing detection of monomeric and trimeric forms of gB under non-reducing conditions 10 and sole predominant staining of gB monomer under reducing conditions (Fig. 1 ). As expected, 11 mAb H126 reacted with gB only under native conditions. Surprisingly, recognition of solely the 12 upper gB protein band > 170 kDa suggests that mAb H126 is trimer specific (Fig.1 ). MAb 2c 13 reacted with native and denatured gB, however, reactivity under denaturing conditions was much 14 weaker compared with mAb H1817 (Fig. 1 ). Weak reactivity with gB monomers under 15 denaturing conditions has been previously reported for a set of other neutralizing antibodies 16 binding to discontinuous epitopes that seem to be either resistant to denaturation or refold during 17 SDS-PAGE electrophoresis and therefore termed "pseudocontinuous" epitopes (4) . 18
To narrow down the conformation-dependent epitope, reactivity of mAb 2c was further 19 characterized using COS-1 cells transiently transfected with plasmids encoding either full-length 20 gB (31-904) or gB mutants with C-terminal truncations at positions 720, 630, 503, 487, and 470. 21
The shortest gB deletion mutant showing positive internal immunofluorescence signals was 22 truncated at position 487 (data not shown). Thus we reasoned that the epitope for mAb 2c is 23 located within residues 31 to 487.
To identify the specific epitope involved in binding of mAb 2c we used gB derived peptides 1 displayed on peptide microarrays. First, the gB sequence displaying amino acids 31 to 505 was 2 prepared by Spot-Synthesis as overlapping 13meric peptides bound with uncharged acetylated 3 amino terminal ends to a continuous cellulose membrane with an offset of 3 amino acids. To 4 avoid shifting of the binding equilibrium for the non-complexed antibody, mAb 2c peptide scans 5 were immobilized on a PVDF membrane prior to detection by chemiluminescence. As shown in 6 the schematic representation of the full length gB with indicated functional domains ( Fig. 2A) , 7 mAb 2c reactivity was restricted to peptides spanning two separate regions within domain I, three 8 consecutive peptides comprising residues 175 to 193 (binding region A) and two overlapping 9 peptides comprising residues 295 to 310 (binding region B). To validate both identified binding 10 regions, we used an additional set of purified 13meric peptides immobilized on glass slides via a 11 flexible linker. Compared to the cellulose screen the read-out of this microarray scanning via 12 fluorescence confirmed the same epitope binding regions (Fig. 2B) . Due to the application of 13 purified peptides and a high resolution microarray scanning system additional consecutive 14 peptides at both binding sites were recognized by mAb2c in this peptide microarray (Fig. 2B) . 15
We mapped the identified binding sites for mAb 2c to the solved gB structure (25). Interestingly, 16 the peptide 172 QVWFGHRYSQFMG 184 showing the strongest reactivity with mAb 2c overlapped 17 with one of the two putative fusion loops (fusion loop 1 173 VWFGHRY 179 ) located in a curving 18 subdomain of domain I (23) (Fig. 3) . However, localization of binding site A at the base of the 19 gB trimer makes it inaccessible to mAb 2c in the available gB structure most likely representing 20 the postfusion conformation (25). Residues of binding site B are exposed and located at the upper 21 part of the domain I (Fig. 3) . 22
To further assess the conformation dependent epitope of mAb 2c, consensus sequences of both 23 binding regions were connected in various combinations as duotopes either directly or separated 24 on July 8, 2017 by guest http://jvi.asm.org/ Downloaded from by one or two ß-alanine spacers (Fig. 4) (Fig. 4) (4, 26, 40, 54) . It has been suggested that neutralizing antibodies, which 20 have been mapped to a unique functional region at the base of the gB trimer comprising residues 21 of the C-terminal end of domain V and residues of domain I of a proximate protomer, interfere 22 with the fusogenic activity of gB (4) . We therefore hypothesized that monovalent antibody 23 binding to the mAb 2c epitope within domain I close to the C terminus of domain V shouldsufficiently block cooperative conformational changes upon activation of gB. Since mAb 2c 1 neutralizes HSV-1 without complement in vitro (17), we generated conventional F(ab') 2 and Fab 2 fragments and a recombinant single chain fragment variable (scFv) as valuable tools for studying 3 the hypothesized mechanism mediated by mAb 2c. The homogeneity of the generated antibody 4 preparations was monitored by size exclusion chromatography (data not shown). 5
Flow cytometry analysis using Vero cells either infected or not infected with HSV-1 or HSV- 2, 6 respectively, demonstrated specific binding of mAb 2c and mAb 2c derived antibody fragments 7 (data not shown). We further used fluorescence cytometry to determine equilibrium binding 8 curves of the antibodies to HSV-1 and HSV-2 infected Vero cells (Fig. 5) . The results of these 9 studies demonstrated higher apparent affinities for the whole IgG and the F(ab') 2 fragment than 10 for the Fab and scFv, respectively ( Table 1 ). The increment in functional affinity (avidity) for the 11 bivalent antibodies relative to the determined affinities of the monovalent antibodies indicates 12 that the bivalent antibodies were able to bind two gB epitopes on the cell surface simultaneously. 13
Bivalent mAb 2c and 2c-F(ab') 2 showed an 1.7-2.8 fold higher apparent affinity compared to 14 their monovalent counterparts. The slight increment in the apparent K D of the F(ab') 2 fragment 15 versus the IgG might be due to the higher flexibility of the antigen binding sites within the 16 F(ab') 2 construct. The similar apparent affinities for mAb 2c, 2c-F(ab') 2 , and 2c-Fab to both, 17 HSV-1 and HSV-2 infected Vero cells confirmed that the recognized gB-epitope does not 18 structurally differ between both viruses (Table 1) . Cell-to-cell spread inhibition. Despite the ability of gB and gD specific monoclonal 3 antibodies for neutralizing HSV-1 with high efficacy, some of them failed to protect cells from 4 viral spread in tissue culture (11, 50). We therefore first compared the mAb 2c efficacy for 5 inhibiting cell-to-cell spread of HSV-1 and HSV-2 in a plaque reduction assay, respectively. As 6 shown in Figure 8 a concentration-dependent reduction of plaque size by mAb 2c was observed 7
for both HSV serotypes. At a concentration of 500 nM, mAb 2c completely abolished HSV-1 8 plaque development (Fig. 8A ). Similarly to the neutralization experiments, a 4-fold higher mAb 9 2c concentration was required to also completely inhibit cell-to-cell transmission in HSV-2 10 infected cells (Fig. 8B) . 11
Although 2c-Fab fragments did not efficiently neutralize free virions, yet it was reported that 12 small sized antibody fragments may exhibit more favourable diffusion properties (68), we 13 investigated their activity for preventing HSV-1 from crossing cell junctions from infected to 14 uninfected cells. For this analysis we employed a more sensitive immunofluorescence assay. Both 15 bivalent antibodies, mAb 2c and 2c-F(ab') 2 , completely abrogated HSV-1 spread in Vero cell 16 monolayers and only single infected cells could be visualized by indirect immunofluoresence 17 (Fig. 9 ). Despite the ability of the polyclonal human serum to neutralize free virions it completely 18 failed to inhibit viral cell-to-cell spread. This is most likely the result of the heterogeneous 19 population of neutralizing antibodies directed against numerous HSV epitopes. Compared with 20 polyclonal human immune serum, the monovalent 2c-Fab fragment was capable to control cell-21 to-cell spread to some extent. In contrast to its bivalent counterparts, however, the monovalent 22 2c-Fab fragment was not able to completely abrogate viral spread even tested at a 6-fold higher 23 3 TCID 50 ) and heart (1.9 x 10 2 TCID 50 ) (data not shown). To assess the 18 therapeutic efficiency of mAb 2c, NOD/SCID mice were treated intravenously with either 2.5 19 mg/kg, 5 mg/kg or 15 mg/kg antibody 24 h prior to intra-vaginal HSV-1 challenge (Fig. 10) . 20
Mice receiving the low antibody doses were not fully protected against lethal infection by HSV-21
1. Median survival times of mice treated with 5 mg/kg mAb 2c, however, were 2.6-fold 22 prolonged when compared to control mice receiving PBS. The HSV-1 titres in the investigated 23 organs from mice not protected against lethal encephalitis were comparable to the untreated 24 within domain I of a proximate protomer (4). Our homology model shows that one part of the 3 discontinuous epitope (F 300 to E 305 ) recognized by mAb 2c localizes to the upper section of 4 domain I of gB, which has characteristics of a pleckstrin homology (PH) domain (7, 39) . The 5 other part of the epitope (F 175 to A 190 ) also located in domain I, however, is buried and would be 6 inaccessible to mAb 2c binding unless gB undergoes a major conformational change. We 7 therefore hypothesized that mAb 2c impedes transition of gB preferentially in the prefusion 8 conformation. Based on the mAb 2c epitope localization and the assumption that conformational 9 changes upon activation are cooperative, we reasoned that monovalent interaction of mAb 2c 10 would be sufficient for blocking juxtaposition of the fusogenic domain of gB and the cellular 11 membrane. Surprisingly, however, none of the generated monovalent antibody fragments (Fab 12 and scFv) was capable to efficiently neutralize free virions or to inhibit viral cell-to-cell spread. 13
In contrast, both bivalent molecules, mAb 2c and 2c-F(ab') 2 antibodies with specificity for the gH antigen of varicella-zoster virus (VZV) has been discussed 2 as a matter of steric hindrance due to the different sizes of these antibodies (16). Although we 3 cannot completely exclude this possibility as a potential additional neutralization mechanism for 4 the mAb 2c variants, this seems unlikely because a direct correlation between antibody size, 5 neutralization efficiency, and cell-to-cell spread inhibition was not observed. Furthermore, our 6 data show that the smaller 2c-F(ab') 2 had an even better virus neutralization activity than the 7 larger 2c-IgG. Hence, the present observations indicate that gB cross-linking is the key 8 mechanism for the antiviral activity of mAb 2c and suggest that stabilization of the gB prefusion 9 conformation through immobilization of gB trimers inhibits activation of the fusogenic signal. A 10 most recent study by Silverman et al. (63) proposed that a fusion-deficient phenotype of the 11 HSV-1 gB ectodomain upon insertion of five amino acids after residue E 187 close to the fusion 12 loop 1 may not result from interference with conformational changes of gB but rather from 13 interference with other mechanistic gB functions. In our duotope scans mAb 2c reacted strongest 14 with binding site A/B duotope 186 FED 188 -βA-βA-300 FYGYRE 305 covering the particular insertion 15 site E 187 , which seems to be critcal for gB function. It is therefore tempting to speculate that mAb 16 2c crosslinking impairs the ability of gB to interact with the other components of the HSV fusion 17 machinery. However, future research is necessary, since our results do not allow to distinguish if 18 cross-linking blocks the conformational change of gB itself or blocks the interaction between gB, 19 gD and gH/gL, which occurs during cell fusion (3) and is essential for completing the fusion 20 process (67). The HSV-1 gB conformation observed in the solved crystals (25) 
